You hand the pharmacist a card. Something happens for four seconds. A number appears — $12, or $340, or "not covered" — and you pay it or you walk out without the medication. The pharmacist did not pick that number, and neither did your doctor or your employer. A company you have never heard of picked it, and Minnesota licenses 52 of them to do exactly that.
They are called pharmacy benefit managers. I want to emphasize how ordinary this is: if you have prescription coverage through work, a PBM is standing between you and the counter right now.
Spread pricing, in plain English
There is not one price for a prescription drug. There are at least three, and they differ on purpose. The manufacturer lists the drug at a wholesale acquisition cost. The PBM pays the pharmacy something else for filling it. The PBM charges your employer's plan something else again. The gap between those last two is the PBM's money.
The arithmetic, in round numbers. A pharmacy dispenses a generic; the PBM reimburses the pharmacy $8, bills the plan $23, and keeps $15. The pharmacist never learns what the plan was billed. The plan never learns what the pharmacist was paid. You, who paid a copay set by a formula neither of them controls, learn nothing at all. That is spread pricing, and nothing about it is hidden from the PBM — it is hidden from both ends, which is the point of standing in the middle.
Minnesota's statute has a word for that gap. Section 62W.06, subd. 1(a)(7)(iii), requires a PBM to disclose to the plan sponsor, on request, "any spread between the net amount paid to the pharmacy in item (ii) and the amount charged to the plan sponsor." Rebates work the same way one layer up: a manufacturer pays the PBM to put its drug on the formulary, and § 62W.02, subd. 2, defines the "aggregate retained rebate" as the share of those rebates "that is not passed on to the pharmacy benefit manager's client." The Legislature named both mechanisms. Naming is not prohibiting.
Two kinds of clawback
A clawback is money taken back after the sale, and Minnesota addresses both directions.
The first hits the pharmacy. A PBM pays a claim, then months later reverses part of it. Section 62W.13 shuts that down: no PBM "shall retroactively adjust a claim for reimbursement submitted by a pharmacy for a prescription drug," unless the adjustment comes out of a pharmacy audit under § 62W.09 or a technical billing error. Two exceptions, both named, and nothing else.
The second hits you. A plan could once collect a $15 copay on a drug the pharmacy would have sold for $4 cash, and the PBM kept the difference. Section 62W.12 forbids requiring an enrollee to pay, at the point of sale, more than the lesser of the copay, the allowable claim amount, or "the amount an enrollee would pay for the prescription drug if the enrollee purchased the prescription drug without using a health plan or any other source of prescription drug benefits or discounts." You cannot be charged more for using your insurance than for not using it — and § 62W.11 kills the gag clause that kept your pharmacist from telling you so.
What chapter 62W actually prohibits — and what it leaves alone
The chapter is the Minnesota Pharmacy Benefit Manager Licensure and Regulation Act (§ 62W.01), enacted in 2019. Since January 1, 2020, no one may act as a PBM in Minnesota without a license from the commissioner of commerce. The application fee is $8,500, the annual renewal is $8,500, and operating without a license runs $5,000 per day.
What it prohibits, section by section: retroactive claim adjustments against pharmacies (§ 62W.13); charging an enrollee more than the cash price at the register (§ 62W.12); gag clauses on pharmacists (§ 62W.11); financial incentives steering you to a pharmacy the PBM owns, unless the same terms are offered at one it does not (§ 62W.07(b)); accreditation standards more stringent than state licensure (§ 62W.05, subd. 3); maximum-allowable-cost prices set below the PBM's own sources, with price lists updated every seven business days and a 15-business-day pharmacy appeal right (§ 62W.08); contingency-fee auditors and extrapolated recoupments (§ 62W.09); and substituting a therapeutic alternative that costs you more out of pocket absent medical reasons (§ 62W.075).
Now what it does not do. The word "spread" appears exactly twice in the entire chapter, both times as a reporting line — once to the plan sponsor on request, once to the commissioner. Minnesota does not ban spread pricing. It does not require rebates to be passed through to the plan or to you. It creates no private right of action, and the words "attorney general" do not appear in chapter 62W at all. Enforcement runs through the commissioner of commerce under chapter 45 (§ 62W.03, subd. 6); the chapter's own route to the Attorney General is a referral from Commerce under § 45.027, subd. 5. Other states have gone further. Minnesota has not, and anyone who tells you otherwise is describing a different state's statute.
Minnesota published the numbers and erased the names
Section 62W.06, subd. 2, is the strongest thing in the chapter. Every licensed PBM must file an annual transparency report with Commerce — aggregate wholesale costs, all rebates, all fees, the retained rebate percentage, and de-identified claims-level detail including the spread on each claim. Commerce must publish the public portion.
It does, and I read the whole file. For calendar year 2024, published July 28, 2025: 52 licensed PBMs, 30 public reports, 19 "zero" reports from companies claiming exemption, and 3 licensees "not responding or missing reports." The prior year — 2023 data, published July 31, 2024 — showed 50 licensed, 28 reports, 20 zeros, 2 missing. The nonresponders went from two to three.
Of the 30 reports for 2024, twelve state a mean retained rebate-and-fee percentage of zero. One states 100 percent. One states negative 714 percent, with a low of negative 27,200 percent, which is not a business result — it is a data-entry error printed as a public record. Commerce says as much in its own Data Limitations: "The data in this report has not been independently audited," and "The public reports in this document are as submitted by the PBMs. Commerce has not vetted or modified the data, unless explicitly noted."
Every one of the 30 is anonymous. The statute directs Commerce to publish without disclosing a plan sponsor's identity or drug-specific prices; it does not, on its face, require hiding the licensee. Commerce hid it anyway, explaining that "[t]o further protect plan sponsor identities, the public reports do not include the name of the submitting PBM." Minnesota has five years of PBM financials on a public website, and no member of the public can attach one of them to a company.
The federal ceiling is real, and it is not where the industry said it was
PBMs argued for years that ERISA — the federal law governing employer plans — preempted state regulation of PBMs outright. The Supreme Court rejected that in Rutledge v. Pharmaceutical Care Management Association, 592 U.S. 80 (2020), upholding Arkansas's reimbursement law: ERISA "does not pre-empt state rate regulations that merely increase costs or alter incentives for ERISA plans without forcing plans to adopt any particular scheme of substantive coverage."
The Eighth Circuit, which covers Minnesota, applied that in Pharmaceutical Care Management Association v. Wehbi, 18 F.4th 956 (8th Cir. 2021) — a case in which Minnesota filed as amicus supporting North Dakota. The court held ERISA preempted none of North Dakota's challenged PBM provisions. But it held Medicare Part D preempted several, including North Dakota's requirement that a PBM owning a pharmacy disclose to the plan sponsor the difference between what it paid the pharmacy and what it charged the sponsor. Minnesota's § 62W.07(a) reads much the same. No court has ruled on the Minnesota provision; searching CourtListener for chapter 62W and for the Act's short title returns no decision construing it. That question is open, and I am not going to close it here.
One more line is worth watching. Wehbi upheld North Dakota's disclosure rules specifically because they required "only the disclosure, upon request, of basic information to pharmacies and plan sponsors" and did not require PBMs "to report to North Dakota the kind of detailed information that ERISA requires plans to report to the Secretary of Labor." Minnesota's § 62W.06, subd. 2, does require claims-level reporting to the state. Nobody has tested it. Someone eventually will.
What the industry says, and where it has a point
The Pharmaceutical Care Management Association is the PBMs' trade association, and its case deserves to be stated the way it makes it. On its website today: PBMs administer drug plans for more than 289 million Americans; they "save payers and patients an average of $1,154 per person per year"; "[f]or every $1 spent on their services, PBMs reduce costs by $10"; and 9 in 10 employers report satisfaction with their PBM. On regulation, PCMA argued in September 2023 that "[r]educing the negotiated rebates and discounts PBMs pass to health plans to lower drug costs for patients and health plans could lead plans to raise premiums to finance drug benefits."
Minnesota's own file supports part of that. The largest 2024 report shows $3.9 billion in wholesale acquisition cost against $1,123,153,000 in manufacturer rebates. Whatever else that company did, it extracted enormous discounts off list price. The same report prints a net wholesale cost of negative $587.7 million, but I am not going to lean on that figure: Commerce's own definitions fold plan-sponsor claims payments into the fees line that drives it below zero, so it is not a measure of discounting. The rebate number alone makes the point. A PBM is not merely a toll booth; it is also a buyer with leverage no single employer has.
Here is the part that costs me. Nothing in chapter 62W lowers what you pay at the counter. Not one section sets a price for a consumer. The statute makes conduct visible and forbids a short list of specific abuses. It does not make your insulin cheaper, and I have found no Minnesota data showing that it did. If the test is your copay, this law has not yet passed it.
What we can do
Put the names on the reports. Amend § 62W.06, subd. 2(b), to state that the public report carries the licensee's name. Plan-sponsor confidentiality is already protected by the same subdivision; a company's own identity is not a plan sponsor's identity. Five years of anonymous financials is a filing cabinet, not transparency.
Audit the data. Commerce publishes these numbers with a written warning that it has not verified them, and a report printing negative 27,200 percent proves the warning is earned. Fund a verification step, or the report is decoration.
Enforce against the three that did not report. Section 62W.06, subd. 3, allows civil penalties up to $1,000 per day per violation, and § 45.027, subd. 7, allows suspension or revocation of a license. Three licensees skipped a mandatory filing for 2024, up from two the year before. Commerce should say publicly what it did about that.
Unlock the spread. Section 62W.06, subd. 1(b), lets a PBM condition disclosure on the plan sponsor signing a nondisclosure agreement, and subd. 2(d) classifies the commissioner's copy of the spread data as confidential, not subject to subpoena, and inadmissible in any private civil action. An employer buying coverage for its own workers should be able to see the spread without signing away the right to talk about it.
Decide, on the record, what the state itself buys. Chapter 62W by its own terms excludes the Department of Human Services from both "pharmacy benefit manager" and "plan sponsor," so Minnesota's largest pharmacy purchases sit largely outside the chapter — two sections, § 62W.07(f) and § 62W.14(b), reach back to PBMs serving plans under contract with Human Services, and nothing else does. That may be right. It should be a decision made in daylight, not a definitional footnote.
A middleman you are not allowed to name is not being watched. He is being filed.
First the facts. Then the fix.
Sources
The statute is Minnesota Statutes chapter 62W, pulled raw from revisor.mn.gov as the full chapter text on September 7, 2026, and read section by section including every History line. Section 62W.01 supplies the short title — the "Minnesota Pharmacy Benefit Manager Licensure and Regulation Act" — and the chapter's operative sections were enacted by 2019 Minn. Laws ch. 39, with later amendments at 2021 Minn. Laws ch. 30 (§ 62W.11), 2022 Minn. Laws ch. 55 (§ 62W.09), and 2023 Minn. Laws ch. 57 (§ 62W.15). The Revisor's chapter page carries a 2026 session note: § 62W.06, subd. 4, has been added by 2026 Minn. Laws ch. 124, art. 3, § 9, which I pulled raw from the session-law text — it directs the commissioner of commerce to share the subd. 2(a) data with the commissioner of health — and which the posted chapter text does not yet incorporate. Every prohibition described above is quoted or paraphrased from the section cited beside it: licensure, the $8,500 application and renewal fees, and the $5,000-per-day unlicensed penalty at § 62W.03; enforcement by the commissioner of commerce under chapter 45 at § 62W.03, subd. 6; spread and retained-rebate reporting at §§ 62W.02, subd. 2, and 62W.06; PBM-owned-pharmacy disclosure and steering at § 62W.07; MAC list updates and appeals at § 62W.08; audit limits at § 62W.09; gag clauses at § 62W.11; point-of-sale limits at § 62W.12; retroactive adjustments at § 62W.13; therapeutic substitution at § 62W.075. That chapter 62W contains no private right of action and no reference to the attorney general is a negative I tested by full-text search of the chapter for "attorney general," "civil action," "cause of action," and "damages": the first, third, and fourth return zero hits, and "civil action" appears only in § 62W.06, subd. 2(d), which bars the commissioner's spread data from private civil actions rather than authorizing one. The attorney-general referral path is § 45.027, subd. 5, and the general $10,000-per-violation penalty is § 45.027, subd. 6, both read raw; the attorney general's enumerated consumer-protection jurisdiction at § 8.31, subd. 1, was read raw and does not list chapter 62W.
The Minnesota numbers come from the Department of Commerce's own filings, downloaded as PDFs and read in full: the Public Pharmacy Benefit Manager Transparency Report, 2024 Data, dated 7/28/2025, and the 2023 Data report dated 7/31/2024. The 2024 file supplies 52 licensed PBMs, 30 public reports, 19 zero reports, 3 nonresponding or missing, the June 2, 2025 filing deadline, and the quoted Data Limitations and PBM-name-masking language; the 2023 file supplies 50, 28, 20, and 2. The distribution of retained rebate-and-fee percentages — twelve reports at a mean of 0 percent, one at 100 percent, one at negative 714 percent with a low of negative 27,200 percent — I computed by reading the "Highest / Lowest / Mean" row of all 30 published reports in the 2024 file. The $3,905,911,000 in wholesale acquisition cost, $1,123,153,000 in rebates, $3,370,439,000 in other fees and payments, $53,444,000 retained, and negative $587,734,000 net wholesale cost are the printed figures on a single masked PBM's 2024 public report, as submitted by that PBM and, by Commerce's own statement, unaudited.
The case law was read on CourtListener, not summarized from a snippet. Rutledge v. Pharmaceutical Care Management Association, 592 U.S. 80 (2020), decided December 10, 2020, reversing 891 F.3d 1109 — the quoted sentence on rate regulation is from the opinion of the Court. Pharmaceutical Care Management Association v. Wehbi, 18 F.4th 956 (8th Cir. 2021), No. 18-2926, filed November 17, 2021 — the ERISA holding, the Medicare Part D holdings including preemption of North Dakota's section 16.2(2) as applied to Part D plans, the quoted distinction about reporting to the Secretary of Labor, and the caption listing the State of Minnesota among amici supporting the appellees all come from the opinion itself. That no decision construes chapter 62W is a negative I tested by searching CourtListener opinions for "62W" (one hit, an unrelated Minnesota tax case) and for the Act's short title (no hits). CourtListener has no citator, so nothing here should be read as a statement about how either case has since been treated.
The industry's position is quoted from the Pharmaceutical Care Management Association's own website, retrieved September 7, 2026: the "Value of PBMs" page for the 289 million figure, the $1,154 per person per year and $1-to-$10 claims, and the employer-satisfaction figure; and PCMA's blog post "Just the Facts," dated September 15, 2023, for the premium argument. Those are PCMA's numbers, presented as PCMA's, and I have not independently verified any of them.
This piece runs about 2,000 words rather than the series' usual 1,100 to 1,400, because chapter 62W runs to eighteen sections and I would not describe its prohibitions by summary. I could not verify PCMA's savings figures against any underlying data, and I do not adopt them. The Commerce PBM webpage is behind a bot filter and could not be retrieved directly; the transparency reports were downloaded from their published mn.gov file paths. Whether § 62W.06's claims-level reporting or § 62W.07(a) survives a federal preemption challenge is undecided, and is described here as undecided. I found no Minnesota data measuring what chapter 62W has done to consumer prescription prices, and I make no claim that it has done anything to them. Corrections: campaign@madgettformn.com.